|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 29, 2019 ) Market Overview
Prostate cancer is the second most frequently diagnosed cancer in the world and the fifth leading cause of cancer death among men. The average age of a prostate cancer diagnosis is 66 years.
However, one-time screening and early diagnosis are likely to increase the success rate of treatment.
Market Drivers
Increasing disease prevalence will act as the primary driver for market growth.
Around 200,000 men are diagnosed with it every year, and most of them are over the age of 50. It is estimated that nearly 30,000 men died because of prostate cancer in 2018.
Other market drivers include rapid advancement in oncology screening and diagnostics as well as innovations in drug development.
However, the high cost associated with diagnostic tests and adverse effects of treatment will affect market growth.
An increasing trend is to bring effective immune-based cancer treatments to patients with prostate cancer.
Immunotherapy is a promising new treatment currently being developed in research. Provence, also known as sipuleucel-T is the only FDA-approved immunotherapy for prostate cancer.
Market Segmentation
The Global Prostate Cancer market report segments the market by therapy, by end-user, and by region.
Based on therapy, the market is segmented into hormonal treatment; chemotherapy; immunotherapy; radiation and focal therapies.
Based on the end user, the global Prostate Cancer market has been segmented into hospitals, ambulatory surgical centers, and specialty clinics.Hospital end-user type segment is expected to account for the highest share.
Geographical Analysis
Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW. North America is the leading global market with the largest revenue share in 2017 owing to the high prevalence of the disease in the US. Next to skin cancer, prostate cancer is the most common cancer in American men. As per the American Cancer Societys, about 164,690 new cases of prostate cancer will be diagnosed in 2018. Hence, this region witnesses high investment in R&D for the development of newer immunotherapies.
Prostate Cancer Market Report Scope
By Therapy Type
Hormone therapy
Chemotherapy
Immunotherapy
Radiation
Focal therapies
By End-User
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
North America (The USA, Canada, Mexico)
South America (Brazil, Argentina, Rest of South America)
Rest of the World.
Enquire Before purchase: https://www.datamintelligence.com/enquiry/prostate-cancer-market
Download free sample: https://www.datamintelligence.com/download-sample /prostate-cancer-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
